‘Exciting Time’ for Pancreas Cancer Treatment as New Device Offers Hope for Improved Lifespan, Quality of Life

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million

November 5, 2026

RenovoRx today announced its financial results for the third quarter ended September 30, 2026 and provided shareholders with a business update highlighting continued commercial momentum and clinical progress.

Treatment Delivers Chemotherapy Directly Near Pancreatic Cancer Tumors

October 30, 2026

A Moffitt Cancer Center patient with locally advanced pancreatic cancer is regaining parts of his daily life after a treatment designed to deliver chemotherapy near the tumor.

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

October 22, 2026

RenovoRx today announced that it will release third quarter 2026 financial results and business highlights after market close on Thursday, November 5, 2026, and host a conference call and webcast at 4:30 p.m. ET.

New Cancer Tech Sends Chemo Straight To Tumors

October 12, 2026

A targeted drug-delivery device may help some pancreatic cancer patients get chemotherapy with fewer body-wide side effects.

‘Exciting Time’ for Pancreas Cancer Treatment as New Device Offers Hope for Improved Lifespan, Quality of Life

Recent News

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million

Treatment Delivers Chemotherapy Directly Near Pancreatic Cancer Tumors

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

New Cancer Tech Sends Chemo Straight To Tumors